SINGLE-CENTER RETROSPECTIVE CLINICAL STUDY ON THE CONDITIONING REGIMEN OF DECITABINE, THIOTEPA, BUSULFAN, AND FLUDARABINE (DTBF) COMBINED WITH ATG/PTCY FOR ALTERNATIVE DONOR TRANSPLANTATION IN MYELODYSPLASTIC NEOPLASMS (EBMT 2026) - Mar 14, 2026 - Abstract #A268; Pres time: Mar 23, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Thiotepa has been demonstrated favorable safety and efficacy in conditioning regimens for transplantation.However, no research data have been reported yet on the DTBF conditioning regimen combined with anti-thymocyte globulin (ATG)/post-transplantation cyclophosphamide (PTCy) in alternative donor HSCT for adult MDS...The GVHD prophylaxis regimen was based on ATG (7.5 mg/kg) combined with low-dose PTCy (29mg/kg), supplemented with cyclosporine, mycophenolate mofetil, and short-course methotrexate...All patients received letermovir for cytomegalovirus (CMV) infection prophylaxis... The preliminary data indicate that the DTBF + ATG/PTCy conditioning regimen demonstrates favorable efficacy and safety for alternative donor-HSCT in adult MDS patients.Future evaluations will involve expanding the patient cohort and extending the follow - up periods."
Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Mucositis • Myelodysplastic Syndrome • Stomatitis • Transplantation
|
|
Shuanghui Yang1; Lang Zou1; Tao Su1; Shujun Li1; Jian Hu1; Kaitai Yang1; Yajing Xu1; Ling Nie1
|